Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1)1
Select Legislative Instrument 2009 No. 62
I, QUENTIN BRYCE, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.
Dated 9 April 2009
QUENTIN BRYCE
Governor-General
By Her Excellency’s Command
NICOLA ROXON
Minister for Health and Ageing
1              Name of Regulations
                These Regulations are the Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1).
2              Commencement
                These Regulations commence on 1 May 2009.
3              Amendment of Health Insurance (Pathology Services Table) Regulations 2008
                Schedule 1 amends the Health Insurance (Pathology Services Table) Regulations 2008.
Schedule 1        Amendments
(regulation 3)
 
[1]           Schedule 1, Part 2, paragraph 13 (7) (b)
substitute
               (b)    more than 1 of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;
[2]           Schedule 1, Part 2, paragraph 25 (4) (a)
after
66539,
insert
66607,
[3]           Schedule 1, Part 2, subrule 25 (5)
after
66551,
insert
66660,
[4]           Schedule 1, Part 2, subrule 25 (5)
omit
, 73314, 73315
[5]           Schedule 1, Part 3, item 66605
substitute
66605
Vitamins — quantitation of vitamins B1, B2, B3, B6 and C in blood, urine or other body fluid
(Item is subject to rule 25)
31.15
[6]           Schedule 1, Part 3, after item 66606
insert
66607
Vitamins — quantitation of vitamins A and E in blood, urine or other body fluid
(Item is subject to rule 25)
76.27
[7]           Schedule 1, Part 3, item 66638
omit
29.70
insert
49.70
[8]           Schedule 1, Part 3, item 66659
omit
in the equivocal range of the particular method of assay used to determine the level
insert
above the age-related median but below the age-related, method-specific 97.5% reference limit
[9]           Schedule 1, Part 3, after item 66659
insert
66660
Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies above the age‑related, method-specific 97.5% reference limit, but below 10 µg/L
(Item is subject to rule 25)
37.80
[10]         Schedule 1, Part 3, after item 66832
insert
66900
Carbon‑labelled urea breath test using oral C‑13 or C‑14 urea, including the measurement of exhaled 13CO2 or 14CO2, (except if item 12533 applies) for:
   (a)  the confirmation of Helicobactor pylori colonisation; or
   (b)  the monitoring of the success of eradication of Helicobactor pylori
78.15
[11]         Schedule 1, Part 3, item 71200
omit
kappa or
insert
kappa and
[12]         Schedule 1, Part 3, item 73049
substitute
73049
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues — 1 identified site
68.60
[13]         Schedule 1, Part 3, item 73059
omit
73049 and 73051
insert
73049, 73051 and 73062
[14]         Schedule 1, Part 3, item 73060
omit
73049
insert
73049, 73062
[15]         Schedule 1, Part 3, item 73060
omit
4 or more
insert
4 to 6
[16]         Schedule 1, Part 3, item 73061
omit
73049
insert
73049, 73062
[17]         Schedule 1, Part 3, after item 73061
insert
73062
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues — 2 or more separately identified sites
89.60

73063
Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority also attends the aspiration for confirmation of sample adequacy
100.00

73064
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051 and 73062 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 7 to 10 antibodies
(Item is subject to rule 13)
72.20

73065
Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051 and 73062 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 11 or more antibodies
(Item is subject to rule 13)
89.60

[18]         Schedule 1, Part 3, item 73300
substitute
73300
Detection of mutation of the FMR1 gene if:
   (a)  the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation; or
   (b)  the patient has a relative with an FMR1 mutation;
1 or more tests
103.10
[19]         Schedule 1, Part 3, item 73314
omit
(Item is subject to rule 25)
[20]         Schedule 1, Part 3, item 73315
omit
, 18A and 25
insert
and 18A
Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.